Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Hypotrichosis

ClinicalTrials.gov lists 660 trials for Hypotrichosis or a narrower condition beneath it. Pfizer has the most among industry and government lead sponsors, with 17.

MeSH D007039 Skin and Connective Tissue Diseases C17
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 62 Phase 1/2 Phase 1/2 33 Phase 2 Phase 2 124 Phase 2/3 Phase 2/3 13 Phase 3 Phase 3 66 Phase 4 Phase 4 42 Not applicable Not applicable 233 Observational Observational 85 Phase 1 Phase 1 62 Phase 1/2 Phase 1/2 33 Phase 2 Phase 2 124 Phase 2/3 Phase 2/3 13 Phase 3 Phase 3 66 Phase 4 Phase 4 42 Not applicable Not applicable 233 Observational Observational 85

Trials per phase

1 more section with rows

13 of the 660 trials are tagged with Hypotrichosis itself; the rest are tagged with a narrower condition beneath it.

Get the Hypotrichosis report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Hypotrichosis trials start? (28)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 3 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 72

1997: 1 trials (Phase 4 1) 1998: 1 trials (Phase 3 1) 2000: 3 trials (Phase 4 2, Phase 1/2 1) 2001: 3 trials (Observational 1, Not applicable 2) 2002: 3 trials (Phase 4 1, Phase 3 1, Phase 2 1) 2003: 4 trials (Phase 4 1, Phase 3 1, Phase 2/3 1, Phase 1 1) 2005: 3 trials (Not applicable 3) 2006: 2 trials (Observational 1, Phase 3 1) 2007: 7 trials (Not applicable 1, Phase 3 1, Phase 2 5) 2008: 5 trials (Phase 3 1, Phase 2 3, Phase 1 1) 2009: 18 trials (Observational 1, Not applicable 8, Phase 4 2, Phase 3 1, Phase 2 6) 2010: 17 trials (Observational 4, Not applicable 2, Phase 4 1, Phase 3 3, Phase 2 5, Phase 1/2 1, Phase 1 1) 2011: 17 trials (Observational 1, Not applicable 4, Phase 4 3, Phase 3 1, Phase 2 5, Phase 1/2 1, Phase 1 2) 2012: 17 trials (Not applicable 6, Phase 3 2, Phase 2 2, Phase 1/2 5, Phase 1 2) 2013: 12 trials (Observational 1, Not applicable 3, Phase 4 1, Phase 3 1, Phase 2 5, Phase 1 1) 2014: 17 trials (Observational 2, Not applicable 6, Phase 4 1, Phase 3 2, Phase 2 4, Phase 1/2 1, Phase 1 1) 2015: 21 trials (Observational 7, Not applicable 8, Phase 3 1, Phase 2 5) 2016: 31 trials (Observational 2, Not applicable 10, Phase 4 3, Phase 3 2, Phase 2 7, Phase 1/2 2, Phase 1 5) 2017: 19 trials (Observational 2, Not applicable 10, Phase 2 4, Phase 1/2 1, Phase 1 2) 2018: 28 trials (Observational 3, Not applicable 7, Phase 4 5, Phase 3 1, Phase 2/3 4, Phase 2 6, Phase 1 2) 2019: 32 trials (Observational 3, Not applicable 14, Phase 4 3, Phase 3 3, Phase 2/3 1, Phase 2 6, Phase 1/2 1, Phase 1 1) 2020: 34 trials (Observational 7, Not applicable 9, Phase 4 2, Phase 3 2, Phase 2/3 1, Phase 2 7, Phase 1/2 1, Phase 1 5) 2021: 39 trials (Observational 4, Not applicable 13, Phase 4 1, Phase 3 6, Phase 2 6, Phase 1/2 2, Phase 1 7) 2022: 56 trials (Observational 7, Not applicable 21, Phase 4 3, Phase 3 2, Phase 2 11, Phase 1/2 3, Phase 1 9) 2023: 72 trials (Observational 10, Not applicable 29, Phase 4 2, Phase 3 9, Phase 2/3 1, Phase 2 11, Phase 1/2 2, Phase 1 8) 2024: 62 trials (Observational 11, Not applicable 30, Phase 4 2, Phase 3 4, Phase 2/3 2, Phase 2 8, Phase 1/2 2, Phase 1 3) 2025: 72 trials (Observational 7, Not applicable 29, Phase 4 4, Phase 3 13, Phase 2 6, Phase 1/2 6, Phase 1 7)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 57
2025 72
2024 62
2023 72
2022 56
2021 39
2020 34
2019 32
2018 28
2017 19

Showing 10 of 28 earlier years.

Start your 14-day trial Email me all 28 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 71 trials starting in 2026 and about 67 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 28 months from start to primary completion across 87 trials still running at the 2026-10-09 snapshot; registered median of 13 months across 357 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Hypotrichosis trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 62
Phase 1/2 33
Phase 2 124
Phase 2/3 13
Phase 3 66
Phase 4 42
Not applicable 233
Observational 85
Expanded access 2

How many Hypotrichosis trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 49
Recruiting 76
Enrolling by invitation 6
Active, not recruiting 39
Available 2

Showing 5 of 9 statuses.

Start your 14-day trial Email me all 9 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Hypotrichosis trials? (7)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Pfizer 17
Aderans Research Institute 11
Allergan 11
Applied Biology, Inc. 9
Suzhou Kintor Pharmaceutical Inc, 9

Showing 5 of 7 sponsors.

Start your 14-day trial Email me all 7 sponsors as a PDF

Which drugs are being tested for Hypotrichosis? (3)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Deuruxolitinib 10
(CP-6890,550) Tofacitinib 9
Dutasteride 6

Interventions as named in the registry (12)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
2% Minoxidil 29
[PRP] platelet rich plasma 18
Ritlecitinib lower dose 17
Triamcinolone Acetonide alone 15
Baritinib 10

Showing 5 of 12 interventions.

Start your 14-day trial Email me all 12 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Hypotrichosis trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Male and female participants on nasal cannula 88 1
87 male and female participants death 87 1
Male and female participants on oxygen mask/bag 69 1
Male and female participants on ventilator 56 1
Hospitalization 38 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Hypotrichosis? (10)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Bimatoprost 0.03% for the Treatment of Eyebrow Hypotrichosis. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 2016 Yes
The Effect of Platelet-Rich Plasma in Hair Regrowth: A Randomized Placebo-Controlled Trial. Stem cells translational medicine 2015 Yes
Minoxidil 2% lotion for eyebrow enhancement: a randomized, double-blind, placebo-controlled, spilt-face comparative study. The Journal of dermatology 2014 Yes
A retrospective review and observational study of outcomes and safety of bimatoprost ophthalmic solution 0.03% for treating eyelash hypotrichosis. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 2014 Yes
Patient-reported outcomes of bimatoprost for eyelash growth: results from a randomized, double-masked, vehicle-controlled, parallel-group study. Aesthetic surgery journal 2013 Yes

Showing 5 of 10 publications.

Start your 14-day trial Email me all 10 publications as a PDF

Sub-conditions in MeSH (1)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages